SCM
AVIR icon

Stonepine Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Stonepine Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-839,514
Closed -$2.56M – 22
2023
Q4 		$2.56M Sell
839,514
-880,486
-51% -$2.67M 1.11% 12
2023
Q3 		$5.16M Buy
1,720,000
+967,912
+129% +$3.29M 1.71% 14
2023
Q2 		$2.81M Buy
752,088
+67,580
+10% +$253K 1.01% 18
2023
Q1 		$2.29M Buy
+684,508
New +$2.78M 0.77% 19

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stonepine Capital Management's AVIR Position: Q1 2024 in Review

Stonepine Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2024, closing a stake of 839,514 shares — an estimated $2.56M sold.

Stonepine Capital Management first reported a position in AVIR in Q1 2023 and held it in 4 quarters. The position peaked at $5.16M in Q3 2023. 113 funds tracked by Wall St. Rank hold AVIR as of Q1 2024.

  • Stonepine Capital Management reported no remaining Atea Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Stonepine Capital Management sold 839,514 Atea Pharmaceuticals shares in Q1 2024, an estimated $2.56M.
  • Stonepine Capital Management first reported a position in Atea Pharmaceuticals in Q1 2023 and held it in 4 quarters.
  • Stonepine Capital Management's Atea Pharmaceuticals position peaked at $5.16M in Q3 2023.
  • 113 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2024.

Based on Stonepine Capital Management's 13F filing for Q1 2024, filed 15 May 2024.